Physician-Directed Patient Self-Management in Heart Failure Using Left Atrial Pressure: Interim Insights from the VECTOR-HF I and IIa Studies
Year: 2024
Type: article
Study design: Clinical Trial
Abstract: AIMS: Haemodynamic monitoring using implantable pressure sensors reduces the risk of heart failure (HF) hospitalizations. Patient self-management (PSM) of haemodynamics in HF has the potential to personalize treatment, increase adherence, and reduce the risk of worsening HF, while lowering clinicians' burden. METHODS AND RESULTS: The VECTOR-HF I and IIa studies are prospective, single-arm, open-label clinical trials assessing safety, usability and performance of left atrial pressure (LAP)-guided HF management using PSM in New York Heart Association class II and III HF patients. Physician-prescribed LAP thresholds trigger patient self-adjustment of diuretics. Primary endpoints include the ability to perform LAP measurements and transmit data to the healthcare provider (HCP) interface and the patient guidance application, and safety outcomes. This is an interim analysis of 13 patients using the PSM approach. Over 12 months, no procedure- or device-related major adverse cardiovascular or neurological events were observed, and there were no failures to obtain measurements from the sensor and transmit the data to the HCP interface and the patient guidance application. Patient adherence was 91.4%. Using PSM, annualized HF hospitalization rate significantly decreased compared to a similar period prior to PSM utilization (0 admissions vs. 0.69 admissions over 11.84 months, p = 0.004). At 6 months, 6-min walk test distance and the Kansas City Cardiomyopathy Questionnaire overall summary score demonstrated significant improvement. CONCLUSIONS: Interim findings suggest that PSM using a LAP monitoring system is feasible and safe. PSM is associated with high patient adherence, potentially improving HF patients' functional status, quality of life, and limiting HF hospitalizations.
DOI: 10.1002/ejhf.3338
Authors: David Meerkin, Leor Perl, Tal Hasin, Shalva Petriashvili, Levan Kurashvili, Mikheil Metreveli, Hüseyin Ince, Sebastian Feickert, Manhal Habib, Oren Caspi, Michael Jonas, Ignacio J. Amat-Santos, Antoni Bayes-Genis, Pau Codina, Oran Koren, Shir Frydman, Rachel M. Pachino, Stefan D. Anker, William T. Abraham, the VECTOR-HF I and IIa Trials Investigators
Institutions: Shaare Zedek Medical Center, Bikur Cholim Hospital, Tel Aviv University, Rabin Medical Center, Hebrew University of Jerusalem, Universitätsmedizin Rostock, Klinikum im Friedrichshain, University of Rostock, Technion – Israel Institute of Technology, Rambam Health Care Campus, Kaplan Medical Center, Centro de Investigación en Red en Enfermedades Cardiovasculares, Hospital Clínico Universitario de Valladolid, Tel Aviv Sourasky Medical Center, German Centre for Cardiovascular Research, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charité – Universitätsmedizin Berlin, The Ohio State University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,250
Funder: European Society of Cardiology
OpenAlex ID: W4399860696
